In clinical trials1,3,4Evidence: Large human trialsMetabolic and weight

Maridebart cafraglutide1

Also called MariTide, AMG 1331

Key takeaway

Maridebart cafraglutide, also called MariTide or AMG 133, is an experimental Amgen drug that joins an antibody to GLP-1-like peptides: it blocks the GIP receptor and activates the GLP-1 receptor.1,2 It is not FDA-approved. Amgen is running Phase 3 trials, and none of the sources reviewed here reports an approval in any country.3,4 In a 52-week randomized Phase 2 trial of 592 people with obesity, average weight change ranged from −12.3% to −16.2% without diabetes, compared with −2.5% on placebo. Gastrointestinal side effects were common.2

Maridebart cafraglutide at a glance

What it isAn investigational antibody-peptide conjugate from Amgen that combines GIP-receptor blocking with GLP-1-receptor activation.1,2
FDA statusNot FDA-approved. Amgen has registered Phase 3 trials on ClinicalTrials.gov, including MARITIME-1 and MARITIME-CV.3,4
Human evidenceA large 52-week randomized, placebo-controlled Phase 2 trial in people with obesity, with or without type 2 diabetes. Phase 3 trials are registered.2,3
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is maridebart cafraglutide?

Maridebart cafraglutide is an experimental drug from Amgen, which ClinicalTrials.gov lists as the sponsor of its trials. It is also known as MariTide and by its development code, AMG 133.1,3

The published Phase 2 report describes it as an antibody-peptide conjugate: an antibody that blocks the GIP receptor, linked to peptides that activate the GLP-1 receptor.2

How is maridebart cafraglutide thought to work?

The drug combines two actions on gut-hormone receptors involved in appetite and blood sugar: it blocks the receptor for GIP and activates the receptor for GLP-1.2

The sources reviewed here do not establish how much each action contributes to the effects reported in trials.2

What do human studies show?

In a 52-week randomized, placebo-controlled Phase 2 trial, 592 people with obesity were assigned to several maridebart cafraglutide groups or placebo. Among the 465 without diabetes, average weight change ranged from −12.3% to −16.2%, compared with −2.5% on placebo.2

Among the 127 with type 2 diabetes, average weight change ranged from −8.4% to −12.3%, compared with −1.7% on placebo. Gastrointestinal events were common.2

Weight change over 52 weeks does not show effects on heart attacks, strokes or other long-term outcomes, which the MARITIME-CV trial is registered to study.2,4

What the evidence base contains

  • Large randomized human trial A 52-week randomized, placebo-controlled Phase 2 trial (NCT05669599) in 592 participants with obesity, 465 without diabetes and 127 with type 2 diabetes, published in The New England Journal of Medicine.2
  • Registered trial without results MARITIME-1 (NCT06858839), a Phase 3 trial in obesity listed as active, not recruiting in its September 17, 2026 registry record, and MARITIME-CV (NCT07037433), a Phase 3 cardiovascular outcomes trial listed as recruiting in its July 24, 2026 record.3,4
  • Registered trial without results A Phase 3 trial in heart failure with obesity (NCT07037459) and a Phase 2 trial in type 2 diabetes (NCT06660173), registered on ClinicalTrials.gov.5,6

Evidence-strength label: Large randomized human trials. How this label is assigned

Is maridebart cafraglutide FDA-approved?

No. Maridebart cafraglutide remains in clinical trials. None of the sources reviewed here reports an approval of maridebart cafraglutide in any country.2,3,4

As of their retained registry records, MARITIME-1, a Phase 3 obesity trial, was listed as active, not recruiting on September 17, 2026, and MARITIME-CV, a Phase 3 cardiovascular outcomes trial, as recruiting on July 24, 2026.3,4

Amgen has also registered a Phase 3 trial in heart failure with obesity and a Phase 2 trial in type 2 diabetes.5,6

Timeline

  1. Results of the Phase 2 obesity trial are published in The New England Journal of Medicine.2
  2. The retained ClinicalTrials.gov record of MARITIME-CV lists the trial as recruiting.4
  3. The retained ClinicalTrials.gov record of MARITIME-1 lists the trial as active, not recruiting.3

What is still unknown?

What the Phase 3 trials will show: their results are not part of the sources cited here.3,4

Its long-term safety and effects on cardiovascular outcomes, which the Phase 2 trial did not measure.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Maridebart cafraglutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Maridebart cafraglutide are the records PeptideScanner has selected and published, not every registration or paper about Maridebart cafraglutide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

In clinical trials; not FDA-approved. A large 52-week randomized Phase 2 trial reported weight loss compared with placebo in people with obesity, with common gastrointestinal side effects. Phase 3 trials, including a cardiovascular outcomes trial, are registered.↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Two selected reports describe early development and a phase 2 trial of an antibody–peptide conjugate combining GIP-receptor antagonism with GLP-1-receptor agonism. Animal experiments and human trial results are separate evidence.↗↗

What the reviewed sources report

The phase 2 trial reported greater weight reduction than placebo over 52 weeks in participants with obesity, with or without type 2 diabetes. Gastrointestinal events were common. These results do not establish long-term clinical outcomes or an approved indication.↗↗

What remains unresolved?

  • What do full trial reports establish about attrition, estimands and discontinuation?↗↗
  • What do subsequent trials and jurisdiction-specific agency records establish?↗↗

Read study designs, results, limitations, and sources →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Maridebart cafraglutide?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

Two selected reports describe early development and a phase 2 trial of an antibody–peptide conjugate combining GIP-receptor antagonism with GLP-1-receptor agonism. Animal experiments and human trial results are separate evidence.12

Bottom line from this bounded source set

The phase 2 trial reported greater weight reduction than placebo over 52 weeks in participants with obesity, with or without type 2 diabetes. Gastrointestinal events were common. These results do not establish long-term clinical outcomes or an approved indication.12

Reviewed study record

Early translational and human program

Design

The publication combines preclinical experiments with an early randomized clinical trial.1

Population

The human trial enrolled people with obesity; animal findings in the same report are not human outcomes.1

Outcomes reported

The authors reported weight reductions in the early human program alongside pharmacologic and preclinical findings.1

Limitations

The abstract does not support a complete participant-flow or harms appraisal. Early exploratory findings cannot establish durable clinical benefit, and the conjugate is not interchangeable with other peptides.1

Reviewed study record

Phase 2 obesity trial

Design

Randomized, placebo-controlled 52-week trial with multiple active groups; NCT05669599.2

Population

592 participants: 465 with obesity without diabetes and 127 with obesity and type 2 diabetes.2

Outcomes reported

In the intention-to-treat analysis, weight changes ranged from −12.3% to −16.2% versus −2.5% without diabetes, and −8.4% to −12.3% versus −1.7% with diabetes. Gastrointestinal events were common.2

Limitations

Multiple groups and two populations should not be pooled into a single effect. Weight is not a direct measure of cardiovascular outcomes, and longer-term safety remains unresolved.2

Reviewed source set

  1. PubMed · 38316982A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. ↗PubMed PMID 38316982 · EFetch XML reviewed 2026-09-15 · payload SHA-256 2c0bc8063119ce5e607f80d3408a47d43f817bd158bcb457a2f27dc8b1305e80
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1038/s42255-023-00966-w. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 40549887Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. ↗PubMed PMID 40549887 · EFetch XML reviewed 2026-09-15 · payload SHA-256 2fa875a73469b01b029c1019de493000ec6d2baebd858aae8cde64d452caf1d1
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2504214. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 1

The first study included an open-label part

Although NCT04478708 has an overall masked-trial designation, its participant-flow description says parts A and B were randomized and blinded while part C was open-label. Treating every participant as part of the same blinded comparison would misdescribe the evidence. NCT04478708 ↗

More findings and the sources behind them

Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.

Posted phase 1 results emphasize exposure and safety

The completed 110-participant phase 1 record posts pharmacokinetic, adverse-event and antibody outcomes. Its results table does not contain a body-weight outcome, so a published weight estimate requires its separate source and analysis context. NCT04478708 ↗

The phase 2 study asks a longer-term weight question

NCT05669599 records 592 participants across cohorts with and without type 2 diabetes. The registered primary endpoint is percentage body-weight change at week 52; the total enrollment is not a single outcome-analysis denominator. NCT05669599 ↗

The larger trial lacks posted registry results in this snapshot

The phase 2 record is marked completed, with a January 20, 2026 last-posted update, but no summary-results section in the retrieved payload. That does not invalidate or replace separately published clinical reports. NCT05669599 ↗

What remains to be checked

  • Appraise the phase 1 and phase 2 publications, including weight outcomes absent from these registry results.
  • Reconcile longer follow-up and adverse-event reporting across blinded and open-label parts.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Scoped identity/name search for initial human evidence synthesis; other aliases and preclinical, extension and combination reports require separate eligibility decisions.

25 retrieved · 2 included · 23 excluded · 0 awaiting a decision · 1 full-text appraisals

Search terms, record decisions and remaining work

"maridebart cafraglutide"[Title/Abstract] OR "AMG 133"[Title/Abstract] OR "maritide"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T13:07:37.694643+00:00 · HTTP 200 · SHA-256 31702a15f51acd783d84e7af9a30c087899e5f9e10260985b61e7cedeeb9cd2e.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T13:05:26.118046+00:00 · HTTP 200 · SHA-256 33e7d893ce860b29b1c22c0c753f8a1ee03a4cf7ca2f820ad5c41a0d1b38827a.

  • Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.
  • Correspondence PMIDs 41337722, 41337723 and 41337724 concerns the phase 2 report; its interpretive implications remain unappraised. These are not counted as separate trials.
  • The phase 1 main article has a structured reading; its November 2024 replacement source-data files and supplements remain unreconciled. The phase 2 primary report still needs full-text appraisal.

Showing 25 of 25 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 40549887 — include: Primary human trial or extension report; the selected abstract establishes the trial identity, while full-text appraisal and registry history remain separate. Study families: NCT05669599.
  2. PubMed 38316982 — include: The main full text and current registry outcomes were read. The appraisal retains cohort-selection, missing-data and corrected source-file limitations; supplements and historical registration remain open. Study families: NCT04478708.
    Structured full-text reading · PMC10896721

    This is an editorial structured reading, not a validated risk-of-bias score.

    Read the source full text (Europe PMC XML) ↗ · NCT04478708 registry record ↗

    Randomization and masking
    The phase 1 study reports double-blind 3:1 randomization against matching-volume saline placebo. Sequential cohorts used sentinel safety review. Allocation-concealment details and the linked protocol have not been independently reconciled.
    Missing data
    The paper reports 75 participants from a 110-person program, excluding intravenous, digital-tool and open-label escalation cohorts. Four participants in the highest multiple-dose cohort withdrew before their second dose after mild gastrointestinal events. Missing data were not imputed, so later observed weight changes must not be read as outcomes for everyone enrolled. The safety section nevertheless reports no events leading to permanent discontinuation; that wording has not been reconciled with the withdrawal account.
    Outcome selection
    Safety was primary, pharmacokinetics secondary and weight change exploratory. The study had no hypothesis-driven power calculation; reported t-tests were post hoc. A November 19, 2024 change-history note says incorrect source-data files were replaced. The replaced files and their numerical impact have not been independently reconciled.
    Applicability
    This small US phase 1 population had obesity without diabetes and excluded important laboratory abnormalities. There was no active comparator. It cannot establish long-term benefit, uncommon harms or the separate contributions of the two receptor actions.
    Funding and conflicts
    Amgen funded the study and participated in design, data collection, analysis, interpretation and publication. Most authors were current or former Amgen employees and stockholders; these relationships matter when interpreting exploratory findings.
    Registry comparison
    The current NCT04478708 record lists 110 enrolled participants, safety as primary and pharmacokinetic outcomes as secondary, consistent with the broader program. The paper reports a 75-person subset. The registry also lists immunogenicity as secondary. Historical outcome versions, the full results tables, protocol and analysis plan remain to be reconciled.

    Reviewed 2026-09-15; source SHA-256 478426a0d5db2904b80277b75c031bfc0e86e4d615de08b17435270cb227511c.

  3. PubMed 42492687 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  4. PubMed 42166683 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  5. PubMed 42568490 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  6. PubMed 42592044 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  7. PubMed 41948476 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  8. PubMed 42198313 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  9. PubMed 41941715 — exclude: Preclinical, genetic or mechanistic study; no primary administration of this molecule to people is reported in the inspected abstract.
  10. PubMed 41054801 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  11. PubMed 41287212 — exclude: Preclinical, genetic or mechanistic study; no primary administration of this molecule to people is reported in the inspected abstract.
  12. PubMed 41337724 — exclude: PubMed identifies a Letter/Comment on PMID40549887, not a separate primary trial report. Correspondence content remains a follow-up interpretation source.
  13. PubMed 41337723 — exclude: PubMed identifies a Letter/Comment on PMID40549887, not a separate primary trial report. Correspondence content remains a follow-up interpretation source.
  14. PubMed 41337722 — exclude: PubMed identifies a Letter/Comment on PMID40549887, not a separate primary trial report. Correspondence content remains a follow-up interpretation source.
  15. PubMed 41093047 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  16. PubMed 40507574 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  17. PubMed 40081498 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  18. PubMed 39723966 — exclude: Preclinical, genetic or mechanistic study; no primary administration of this molecule to people is reported in the inspected abstract.
  19. PubMed 38843460 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  20. PubMed 38871982 — exclude: Preclinical, genetic or mechanistic study; no primary administration of this molecule to people is reported in the inspected abstract.
  21. PubMed 38763780 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  22. PubMed 38388678 — exclude: The publisher identifies this item as a Research Highlight and links the original AMG 133 study. It is secondary coverage, not another primary human-administration report.

    Eligibility source ↗ · Article classification: Research Highlight; original-article reference · read 2026-09-15.

  23. PubMed 36509857 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  24. PubMed 36608818 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
  25. PubMed 34176426 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"MARIDEBART CAFRAGLUTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:21.076391+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Maridebart cafraglutide", "MariTide", "AMG 133"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

      2 retrieved · 0 included · 0 excluded · 2 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["Maridebart cafraglutide", "MariTide", "AMG 133"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      1. EMA 68677 — not screened: Title-name match awaiting identity and document review. P/0131/2024: EMA decision of 11 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for GIPR antagonist/GLP-1R agonist (AMG 133) (EMEA-003439-PIP02-23)
      2. EMA 74476 — not screened: Title-name match awaiting identity and document review. EMA/PE/0000239753 : EMA decision of 24 April 2025 on the granting of a product specific waiver for maridebart cafraglutide

      EMA search

      Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["Maridebart cafraglutide", "MariTide", "AMG 133"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        ClinicalTrials.gov search

        ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

        27 retrieved · 0 included · 0 excluded · 27 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        "Maridebart cafraglutide" OR "MariTide" OR "AMG 133"

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T11:26:38.824629+00:00 · HTTP 200 · SHA-256 11f1adb0ee8be68fdef301c1d2e7b6ac530120604122d76f98e0e640b7831493.

        • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
        • Other registries, unregistered studies and additional aliases remain outside this query.

        Showing 25 of 27 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        1. ClinicalTrials.gov NCT06858878 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        2. ClinicalTrials.gov NCT07313761 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        3. ClinicalTrials.gov NCT07429032 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        4. ClinicalTrials.gov NCT06987695 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        5. ClinicalTrials.gov NCT07523711 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        6. ClinicalTrials.gov NCT07037433 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        7. ClinicalTrials.gov NCT07441252 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        8. ClinicalTrials.gov NCT07160257 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        9. ClinicalTrials.gov NCT07428525 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        10. ClinicalTrials.gov NCT07226778 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        11. ClinicalTrials.gov NCT07684235 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        12. ClinicalTrials.gov NCT07684144 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        13. ClinicalTrials.gov NCT07717814 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        14. ClinicalTrials.gov NCT06858839 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        15. ClinicalTrials.gov NCT07229157 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        16. ClinicalTrials.gov NCT05056246 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        17. ClinicalTrials.gov NCT07429045 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        18. ClinicalTrials.gov NCT07310563 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        19. ClinicalTrials.gov NCT06660173 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        20. ClinicalTrials.gov NCT05669599 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        21. ClinicalTrials.gov NCT07226765 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        22. ClinicalTrials.gov NCT04478708 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        23. ClinicalTrials.gov NCT07575399 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        24. ClinicalTrials.gov NCT06976372 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        25. ClinicalTrials.gov NCT06352892 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        Explore status sources, recent additions, and coverage gaps

        Living status brief

        What is the current status of Maridebart cafraglutide?

        In clinical trials; not FDA-approved. A large 52-week randomized Phase 2 trial reported weight loss compared with placebo in people with obesity, with common gastrointestinal side effects. Phase 3 trials, including a cardiovascular outcomes trial, are registered.↗↗↗↗

        The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

        Evidence present

        What records are connected here?

        Evidence lanes
        2
        Source years
        2
        Drugs@FDA applications
        0

        These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

        Coverage gaps

        What remains unknown or unsupported?

        PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

        PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

        Explore the Evidence Map and record counts

        Evidence Map v1

        What kinds of records connect to Maridebart cafraglutide?

        Compare collection coverage →

        This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

        23Selected dated records
        24Connected citations
        2Populated source years2025–2026
        2/4Record lanes present

        Registered human studies

        Trial composition

        13 of 19 selected trial records include at least one phase value; 13 of 19 include a status value in the retained structured contract.

        126 public history versions connect to 9 of these trial records across 2 submitted years. Open the record-history collection →

        PhasesPhase 3 7Phase 1 5Phase 2 1
        Status at observationRecruiting 7Active, not recruiting 2Completed 2Not yet recruiting 2

        A phase value is unavailable here for 6 selected records; this is not counted as “no phase.”

        A status value is unavailable here for 6 selected records; this is not counted as a trial status.

        PubMed bibliography

        Publication composition

        1 of 4 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

        Publication typesJournal Article 1Review 1

        Bibliography fields unavailable here for 3 selected records; the records remain visible as metadata observations.

        Regulatory and publication surfaces

        What is structurally connected?

        Drugs@FDA applications
        0
        FDA Federal Register documents
        0
        DailyMed SPL versions
        0
        Canonical profile
        Published
        Profile structured data
        Published
        Linked dated records
        23

        Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

        Profile publication history and record counts
        Source records by collection · 23 dated records

        Research hub

        Explore the Maridebart cafraglutide evidence record

        Open all 23 records →
        23Dated records
        2Evidence types
        23Cited public sources
        2Source years

        Change ledger

        Recently changed for Maridebart cafraglutide

        Open all 25 events →

        PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

        Profile status changed

        Maridebart cafraglutide profile

        We added a plain-language reader guide with cited answers, Phase 2 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 3 trials.

        PeptideScanner change date
        November 14, 2026
        Evidence lane
        Profile
        Record added

        ClinicalTrials.gov record NCT06660173

        PeptideScanner retained ClinicalTrials.gov record NCT06660173 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

        PeptideScanner change date
        November 14, 2026
        Cited source date
        September 11, 2026
        Evidence lane
        Clinical trials
        Record added

        ClinicalTrials.gov record NCT06858839

        PeptideScanner retained ClinicalTrials.gov record NCT06858839 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

        PeptideScanner change date
        November 14, 2026
        Cited source date
        September 17, 2026
        Evidence lane
        Clinical trials

        Official-source collections

        Source records for Maridebart cafraglutide

        Open the full research atlas →
        ClinicalTrials.gov18

        126 public history versions across these dated registry records; status labels apply only to each cited observation.

        1. NCT07871409Registry update November 9, 2026 · current at observation
        2. NCT07921316Registry update November 6, 2026 · current at observation
        3. NCT07908316Registry update November 2, 2026 · current at observation
        Explore all selected trial records →Explore all public record history →

        Evidence types

        Coverage by source year

        Selected records span December 3, 2025 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

        Continue exploring

        Profiles with overlapping source-year coverage

        Open the research atlas →

        These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

        Organizations and trial records named in cited sources

        Organizations named in cited records

        • Amgen1

        Trial records

        Dated updates connected to this profile · 23

        Updates connected to this profile

        Open the full cross-source timeline →
        1. Clinical trials

          ClinicalTrials.gov record NCT07871409↗

          PeptideScanner retained ClinicalTrials.gov record NCT07871409 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        2. Clinical trials

          ClinicalTrials.gov record NCT07921316↗

          PeptideScanner retained ClinicalTrials.gov record NCT07921316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        3. Clinical trials

          ClinicalTrials.gov record NCT07908316↗

          PeptideScanner retained ClinicalTrials.gov record NCT07908316 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        4. Clinical trials

          ClinicalTrials.gov record NCT07310563↗

          PeptideScanner retained ClinicalTrials.gov record NCT07310563 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        5. Clinical trials

          ClinicalTrials.gov record NCT07832799↗

          PeptideScanner retained ClinicalTrials.gov record NCT07832799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        6. Clinical trials

          ClinicalTrials.gov record NCT06858839↗

          PeptideScanner retained ClinicalTrials.gov record NCT06858839 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        7. Clinical trials

          ClinicalTrials.gov record NCT06660173↗

          PeptideScanner retained ClinicalTrials.gov record NCT06660173 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        8. Clinical trials

          ClinicalTrials.gov record NCT07684144↗

          PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        9. Clinical trials

          ClinicalTrials.gov record NCT07575399↗

          PeptideScanner retained ClinicalTrials.gov record NCT07575399 at 2026-09-09T19:17:17.083Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        10. Literature metadata

          Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.↗

          PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        11. Clinical trials

          ClinicalTrials.gov record NCT07313761↗

          PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        12. Clinical trials

          ClinicalTrials.gov record NCT07684235↗

          PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗

        Citations

        Sources

        Coverage and sources →

        Numbered markers in the text point here. Each link opens the original public record.

        1. 1
          Bioavailability of AMG 133 in Participants With Overweight or Obesity · record history version 1 · last update posted 2026-07-21 ↗

          ClinicalTrials.gov · Official source · Source checked July 22, 2026

        2. 2
          Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial (2025) · PMID 40549887 ↗

          The New England Journal of Medicine · Official source · Source checked November 14, 2026

        3. 3
          ClinicalTrials.gov record NCT06858839 · retained source version 2026-09-17:beb2c75eb0a3bc43ffe1b4c9fab269e89fcf8ae6cbe11f7d4c3ea4213aed3e04 ↗

          ClinicalTrials.gov · Official source · Source checked November 14, 2026

        4. 4
          ClinicalTrials.gov record NCT07037433 · retained source version 2026-07-24:ae9704758762002a715a9ed9f57da8845f1a2ea224c8296b8200071653366d78 ↗

          ClinicalTrials.gov · Official source · Source checked August 13, 2026

        5. 5
          ClinicalTrials.gov record NCT07037459 · retained source version 2026-07-02:199638062a19e7df645ce1f76202d15ba272ee303ca7769667116afd6858e958 ↗

          ClinicalTrials.gov · Official source · Source checked August 13, 2026

        6. 6
          ClinicalTrials.gov record NCT06660173 · retained source version 2026-09-11:dfcf2dd8720eee75605fef185ae1153439869797ef1a2e2f6d827aef846b701b ↗

          ClinicalTrials.gov · Official source · Source checked November 14, 2026